Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the efficacy and safety of 14-day quadruple therapy based on fecal molecular antimicrobial susceptibility tests for the first-line eradication of H. pylori infection, thus, providing more evidence to inform the value of fecal antimicrobial susceptibility tests in the first-line treatment of H. pylori infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Treatments: Amoxicillin; Bismuth; Clarithromycin; Furazolidone; Rabeprazole

Criteria

Inclusion Criteria:

1. Helicobacter pylori-positive participants determined by ¹³C-urea breath test, ¹⁴C-urea breath test, HE stain, or bacterium culture

2. With no historical treatment for helicobacter pylori infection

3. Have undergone an endoscopy before the eradication treatment if they have alarm symptoms, a family history of gastric cancer, or age over 40 years old without undergoing an endoscopy before

Exclusion Criteria:

1. Administration of antibiotics, bismuth in 4 weeks prior to inclusion or antacids including H2 receptor antagonist, proton pump inhibitor, and potassium-competitive acid blocker in 2 weeks prior to inclusion

2. Active peptic ulcer with complications such as hemorrhage, perforation, obstruction, cancerization, etc.

3. With previous esophageal or gastric surgery

4. With severe systemic diseases, major organs like heart, lung, brain diseases, liver or kidney insufficiency, malignant tumor, or other diseases

5. Allergy to any of the study drugs

6. Pregnancy or lactation

7. Participated in other research within 3 months, cannot express his/her own ideas correctly or cannot cooperate with the researcher